Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high269.75 11/09/17
52 week low88.25 19/09/16
52 week change 99.00 (108.79%)
4 week volume1,158,960 24/08/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before Expenses

Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before Expenses NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Sum...

Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment Option

Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment Option NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc...

Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses

Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTIO...

Summit awarded Barda contract worth up to $62m

Summit Therapeutics has announced that the Biomedical Advanced Research and Development Authority (BARDA) has ...

Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI

Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI Summit Therapeutics plc ('Summit Therapeutics', Summit', or the 'Company') SUMMIT AWARDED BARDA CONTRACT WORTH UP TO $62 MILLION TO SUPPORT THE DEVELOPMENT OF RIDINILAZOLE FOR THE TREATMENT OF...

Summit announces positive ridinilazole trial results

Summit Therapeutics has announced positive top-line data from an exploratory Phase 2 clinical trial that support ridinilaz...

Summit Therapeutics plc : Positive Top-line Phase 2 Results

Summit Therapeutics plc: Positive Top-line Phase 2 Results Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT ANNOUNCES POSITIVE TOP-LINE DATA FROM AN EXPLORATORY PHASE 2 CLINICAL TRIAL SUPPORTING RIDINILAZOLE AS A HIGHLY SELECTIVE ANTIBIOTIC FOR THE TREATMENT OF CDI Ridinilazole treatment mo...

Summit Therapeutics plc : Half-yearly report

Summit Therapeutics plc: Half-yearly report Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 AND OPERATIONAL PROGRESS Conference Call Scheduled for 1:00pm BST / 8:00am EDT Oxford, UK, 31 Aug...

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Dilution

    So after todays press release all of the gain made following the previous press release has been wiped out in one foul swoop. It seems every time we get a decent rise in the ...
    14-Sep-2017
    scep
  • Re: NEW ARTICLE: Four AIM shares for a p...

    ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...
    6-Jul-2017
    bobsson
  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...
    18-Jun-2017
    pharmaspecialist

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.22%
RANGE RES.20%
ROYAL BANK SCOT17%
SIRIUS MINERALS15%
ROCKHOPPER13%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM